DDInter624 DDInter1026
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Saquinavir
Saquinavir {u} may lead to a major life threatening interaction when taken with {v} Larotrectinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Escitalopram
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Nevirapine
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Larotrectinib
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C19 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Voriconazole
Voriconazole {u} may lead to a major life threatening interaction when taken with {v} Larotrectinib
Efavirenz {u} (Compound) upregulates {v} (Gene) TBX2
TBX2 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Cytochrome P450 2C19 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Oritavancin
Oritavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Levonorgestrel
Levonorgestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Saquinavir (Compound) and Saquinavir may lead to a major life threatening interaction when taken with Larotrectinib
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Escitalopram (Compound) and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Nevirapine (Compound) and Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Efavirenz (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is upregulated by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Larotrectinib
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) includes Voriconazole (Compound) and Voriconazole may lead to a major life threatening interaction when taken with Larotrectinib
Efavirenz (Compound) upregulates TBX2 (Gene) and TBX2 (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C19 Inhibitors (Pharmacologic Class) includes Oritavancin (Compound) and Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Efavirenz (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib